| Document |
Document Title |
|
WO/2024/037531A1 |
Provided are an anti-PSMA single-chain antibody, a chimeric antigen receptor associated therewith and use thereof. An amino acid sequence of a heavy chain of the anti-PSMA single-chain antibody includes a sequence shown in SEQ ID NO: 1, ...
|
|
WO/2024/040207A1 |
Genetically engineered NK cells, which express at least one metabolism modulating polypeptides and optionally a chimeric receptor polypeptide (e.g., an antibody-coupled T cell receptor (ACTR) polypeptide or a chimeric antigen receptor (C...
|
|
WO/2024/040013A1 |
Disclosed herein is a three dimensional (3D) culture system for high-throughput screening with pumpless perfusion. It is a two well flow system where one well has a membrane at the bottom and the other is open. Both wells are connected s...
|
|
WO/2024/036387A1 |
The present invention relates to a concentrate of proteins and peptides derived from mesenchymal stem cells that can be used by the pharmaceutical, veterinary, cosmetic or food industries. The protein and peptide concentrate derived from...
|
|
WO/2024/039683A1 |
Compositions and methods for therapeutic use of engineered myeloid cells are described. Methods for increasing therapeutic effectiveness of immune cells by use of an immune cell inhibitory agent prior to therapy is described. Effective u...
|
|
WO/2024/039619A1 |
Embodiments described herein generally provide for expanding cells in a cell expansion system. The cells may be grown in a bioreactor, and the cells may be activated by an activator (e.g., a soluble activator complex). Nutrient and gas e...
|
|
WO/2024/040145A1 |
Systems and methods consistent with the present disclosure relate to MicroOrganoSpheres (MOSs). More particularly, methods relate to delivering components into a MOS. The methods also relate to delivering components into a MOS for screen...
|
|
WO/2024/037011A1 |
Provided are a culture medium and a method for inducing iPSC differentiation to obtain macrophages and use thereof, which relate to the technical field of biopharmaceutics. The culture medium comprises from a first-stage culture medium t...
|
|
WO/2024/037724A1 |
The disclosure provides methods for improving sperm function and fertilizing ability for assisted reproduction techniques. The methods provided by the disclosure, in some embodiments entail sequential changes of temperature, bicarbonate ...
|
|
WO/2024/037461A1 |
Provided are an engineered immune cell and a preparation method therefor. The engineered immune cell is prepared by means of transfecting an isolated nucleic acid molecule. The isolated nucleic acid molecule comprises: a nucleic acid seq...
|
|
WO/2024/037654A1 |
Provided are tissue engineering cartilage constructed based on a decalcified bone scaffold, a preparation method therefor, and use thereof in the repairing of joint defects. A marrow fluid of a patient is extracted, bone marrow mesenchym...
|
|
WO/2024/039216A1 |
The present invention relates to: an animal cell culture medium composition; a method for culturing animal cells using same; a method for preparing a non-human animal cell line; a cell line prepared using same; and a method for culturing...
|
|
WO/2024/038497A1 |
Provided is a promoter comprising any one DNA of (1) to (4) below. (1) a DNA including the base sequence represented by any one of SEQ ID NOs: 1 to 3; (2) a DNA having promotor activity and including a base sequence in which one or more ...
|
|
WO/2024/040201A1 |
The present disclosure provides methods and apparatuses for improved cell therapy and personalized medicine. The present disclosure further provides computer-readable media encoding computer-readable instructions for causing one or more ...
|
|
WO/2019/243537A9 |
The present invention relates to an accelerated method to generate high yields of type-1 polarizing mRNA loaded dendritic cells for use in immunotherapy, and in particular for use in cancer vaccination.
|
|
WO/2023/226921A9 |
The present invention provides a bispecific chimeric antigen receptor targeting BCMA-CD19 and an application thereof. The bispecific chimeric antigen receptor comprises an extracellular antigen recognition domain; the extracellular antig...
|
|
WO/2024/039236A1 |
The present application relates to a system for substance delivery and gene editing in germ cells using exosomes. Exosomes with a target substance (such as foreign genes) inserted therein according to one aspect enable target substance d...
|
|
WO/2024/038449A1 |
A method for identification of a multipotent mesenchymal stem cell subpopulation, among a heterogenic population of gastrointestinal tract mucosa mesenchymal stromal cells, is provided. Further provided is a kit including a probe for ide...
|
|
WO/2024/038118A1 |
The invention is based on a pooling strategy and cell passaging strategy for mesenchymal stromal cells (MSCs), which provide highly active master bank cell preparations and working bank cell preparations which can be directly used or, af...
|
|
WO/2023/129429A9 |
Enamel forms during early development, before the tooth breaks through the gum, and it covers the visible portion of the tooth. During development, epithelial cells within the enamel organ differentiate into ameloblasts, which produce th...
|
|
WO/2024/040123A1 |
The present disclosure relates generally to methods and systems of producing Schwann cells from pluripotent stem cells under fully defined conditions. The Schwann cells produced by the disclosed methods find applications as models of the...
|
|
WO/2024/037477A1 |
The present invention relates to a bispecific chimeric antigen receptor, and an immune cell, a preparation method, an application and a tumor treatment drug. Provided is a bispecific chimeric antigen receptor, the chimeric antigen recept...
|
|
WO/2024/039036A1 |
The present invention relates to a transplantable cell therapy product composition for diabetes mellitus that contains an aggregate of insulin-secreting cells derived from stem cells. In the present invention, an NF microwell array membr...
|
|
WO/2023/159221A9 |
Described here are VHH antibody libraries with heavy chain variable domains framework scaffolds having complementary determining regions (CDRs) found in naturally-occurring human antibodies, and methods of making such antibody libraries....
|
|
WO/2024/036600A1 |
Disclosed in the present invention are an autonomous parthenogenetic haploid reproduction method for maternal cells and use thereof in breeding. The present invention provides a method for obtaining a parthenogenetic haploid of corn, com...
|
|
WO/2024/040032A1 |
The present disclosure relates generally to the manipulation of chimeric polypeptide signaling to decrease cancer cell proliferation, and particularly to a new class of receptors engineered to (i) bind a target cell-surface displayed lig...
|
|
WO/2024/036839A1 |
Provided are a gene-modified cell drug expressing phenylalanine hydroxylase (PAH), a method for preparing same, and use thereof. The gene-modified cell drug expressing PAH comprises a cell modified by the human normal phenylalanine hydro...
|
|
WO/2024/040138A1 |
A population of universal natural killer (NK) cells derived from human pluripotent stem cells (hPSCs) and engineered to overexpress the transcription factor ID2, NFIL3, and/or SPI1 and, optionally, an anti-programmed death ligand 1 (PD-L...
|
|
WO/2024/035130A1 |
The present invention relates to a method for selective differentiation from a pluripotent stem cell to hindbrain tissue, the method comprising a step of selective differentiation into hindbrain tissue, in which embryoid bodies formed fr...
|
|
WO/2024/034559A1 |
The present invention provides a method for mass producing cell aggregates such as artificial organoids through an approach that differs entirely from previous methods. Specifically, provided is a method for producing cell aggregates tha...
|
|
WO/2023/101603A9 |
The invention concerns a novel therapeutic comprising a secretome obtained from mesenchymal stem cells of umbilical cord tissue or of wharton's jelly tissue and a formulation or pharmaceutical composition including same; ideally, but not...
|
|
WO/2024/033300A1 |
The present disclosure relates to a method for the generation of cells of the pancreatic lineage, for example pancreatic islet-like cell aggregates comprising pancreatic β–cells, which method comprises the steps of providing a single ...
|
|
WO/2024/035104A1 |
The present invention relates to a cell-DNA hydrogel complex and a method for producing same. In the cell-DNA hydrogel complex of the present invention, cells with a first functional group protruding from the surface thereof and a DNA hy...
|
|
WO/2024/036234A1 |
Disclosed herein are systems and methods for screening variant libraries for activity. Also disclosed herein are high throughput methods for identifying candidate variant having gain of function biological activity in an assay. The discl...
|
|
WO/2024/035964A1 |
Featured are compositions and methods for an ovarian implant comprising ovarian support cells. In particular, the disclosure features methods of culturing ovarian support cells for the purpose of implantation into a subject in need there...
|
|
WO/2024/033385A1 |
The present invention relates to silk fibroin-based scaffolds suitable for supporting the 3D culture of human hematopoietic stem and progenitor cells and/or the production of blood cells ex-vivo, and methods for producing the same.
|
|
WO/2024/031188A1 |
There is provided a composition for modifying a T cell, the composition comprising: a protein complex comprising a polynucleotide-modifying enzyme domain, a T cell membrane binding domain and an endosome escape domain; a guide oligonucle...
|
|
WO/2024/035733A1 |
The present disclosure is generally directed to the use of biomaterial scaffolds engineered with SA-FasL for the transplantation of stem cell derived β-cells as a treatment for Type I diabetes. Early engraftment post-transplantation and...
|
|
WO/2024/033284A1 |
The invention relates to a cellular microcompartment that can be used clinically, termed "GMP", comprising at least: a. a cell layer, b. an external hydrogel layer, and c. a fibrin mesh placed between the external hydrogel layer and said...
|
|
WO/2024/032247A1 |
Provided are a CLL1 antibody and use thereof. The CLL1 antibody or an antigen-binding site thereof comprises a heavy chain variable region and a light chain variable region, wherein the amino acid sequences of CDR1, CDR2, and CDR3 of the...
|
|
WO/2024/032485A1 |
The present invention relates to a non-phosphorylated and non-ubiquitinated CREPT protein and use thereof. Specifically, the present invention relates to a protein that is obtained by modifying CREPT or a homologous protein thereof. The ...
|
|
WO/2024/036106A1 |
A non-human animal comprising chimeric microglia and methods of performing blastocyst microglia complementation to produce such a non-human chimeric animal are disclosed. In particular, the disclosed methods can be used to produce a non-...
|
|
WO/2024/031181A1 |
Breast cancer is now the most prevalent cancer worldwide, and despite therapeutical advances in the last decades, metastatic breast cancer remains an incurable disease. Novel tumor-specific antigens (TSAs) and tumor-associated antigens (...
|
|
WO/2024/036005A1 |
A method for treating Alzheimer's disease is disclosed. The method comprises identifying a subject and treating the subject with expanded natural killer cells (NKs). A composition for treating Alzheimer's disease is also disclosed.
|
|
WO/2024/033299A1 |
The present disclosure relates to a method for the generation of cells of the pancreatic lineage, for example pancreatic β–cells, which method comprises a step of culturing a cell population of posterior foregut cells under conditions...
|
|
WO/2024/034631A1 |
The present invention is a modified fibroin that contains a domain sequence represented by formula 1: [(A)n motif-REP]m or formula 2: [(A)n motif-REP]m-(A)n motif and has a GQ motif content of 12.5% or less. (In formulae 1 and 2, (A)n mo...
|
|
WO/2024/033879A1 |
The present disclosure relates to modified cells, e.g., chimeric antigen receptor (CAR) T cells and/or exogenous T cell receptor (eTCR) cells, which have reduced in vivo immunogenicity, and the use thereof.
|
|
WO/2024/035134A1 |
The present invention relates to a method for preparing a cerebellar organoid, comprising: (A) a step of selective differentiation into hindbrain tissues, in which an embryonic body formed from pluripotent stem cells is cultured in the p...
|
|
WO/2024/035132A1 |
The present invention relates to a method for selective differentiation into dorsal-metencephalic tissue from embryoids derived from pluripotent stem cells, the method comprising the step of selective differentiation into dorsal-metencep...
|
|
WO/2024/032486A1 |
The present invention relates to a CREPT mutant and use thereof in the inhibition of tumor growth. In particular, the present invention relates to a protein obtained by replacing a residue at position 134 of SEQ ID NO: 4 with a residue t...
|
